Phaseline

Companies › Inhibrx Biosciences

Inhibrx Biosciences: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 2 Phase 2, 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
INBRX-109
Tetravalent DR5 agonist antibody
TNFRSF10BPhase 2Conventional Chondrosarcoma; Ewing SarcomaDec 2026
INBRX-106
OX40 receptor agonist antibody
TNFRSF4Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC); Solid TumorDec 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04950075INBRX-109Phase 2Conventional ChondrosarcomaOncologyDec 2026
NCT03715933INBRX-109Phase 1Ewing SarcomaOncologyDec 2028
NCT06295731INBRX-106Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC)OncologyDec 2029
NCT04198766INBRX-106Phase 1Solid TumorOncologyJul 2033

From the company's SEC filings

Cash of $133m on 2026-06-30; operating cash outflow about $138m a year; runway about 12 months at that burn, to Jun 2027; 1 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

TNFRSF4 (1) TNFRSF10B (1)

Companies with the same targets

Regeneron Pharmaceuticals GSK

Companies built like this

Neonc Technologies Dogwood Therapeutics Atossa Therapeutics Curis Oncolytics Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.